D Vasmant

421 total citations
44 papers, 328 citations indexed

About

D Vasmant is a scholar working on Cardiology and Cardiovascular Medicine, Nephrology and Pharmacology. According to data from OpenAlex, D Vasmant has authored 44 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 8 papers in Nephrology and 5 papers in Pharmacology. Recurrent topics in D Vasmant's work include Blood Pressure and Hypertension Studies (12 papers), Renal Diseases and Glomerulopathies (7 papers) and Pharmacogenetics and Drug Metabolism (4 papers). D Vasmant is often cited by papers focused on Blood Pressure and Hypertension Studies (12 papers), Renal Diseases and Glomerulopathies (7 papers) and Pharmacogenetics and Drug Metabolism (4 papers). D Vasmant collaborates with scholars based in France, Germany and Australia. D Vasmant's co-authors include Michèle Maurice, A Bensman, N. Bender, Athanase Bénétos, Michel Marre, A Carré, M. E. Safar, Michel Lièvre, Michel E. Safar and Gilles Châtellier and has published in prestigious journals such as Biochemical Pharmacology, Pediatric Research and The Anatomical Record.

In The Last Decade

D Vasmant

42 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D Vasmant France 10 128 97 66 44 43 44 328
Toshie Segawa Japan 10 176 1.4× 57 0.6× 49 0.7× 37 0.8× 36 0.8× 16 325
P.E. de Jong Netherlands 12 172 1.3× 189 1.9× 103 1.6× 33 0.8× 51 1.2× 15 415
A. Chachati Belgium 5 135 1.1× 227 2.3× 153 2.3× 29 0.7× 35 0.8× 9 417
Seema Basi United States 4 99 0.8× 120 1.2× 102 1.5× 27 0.6× 83 1.9× 7 328
A. Ligabue Italy 11 104 0.8× 91 0.9× 66 1.0× 39 0.9× 94 2.2× 21 464
Luis Revert Spain 9 75 0.6× 132 1.4× 56 0.8× 123 2.8× 50 1.2× 14 361
Gerjan Navis Netherlands 11 160 1.3× 133 1.4× 100 1.5× 53 1.2× 101 2.3× 15 415
Pierre F. Faubert United States 10 187 1.5× 212 2.2× 71 1.1× 78 1.8× 50 1.2× 17 443
J.-P. Chapelle Belgium 10 78 0.6× 79 0.8× 41 0.6× 34 0.8× 33 0.8× 23 340
M. C. Laver Australia 11 65 0.5× 53 0.5× 54 0.8× 57 1.3× 86 2.0× 12 380

Countries citing papers authored by D Vasmant

Since Specialization
Citations

This map shows the geographic impact of D Vasmant's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D Vasmant with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D Vasmant more than expected).

Fields of papers citing papers by D Vasmant

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D Vasmant. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D Vasmant. The network helps show where D Vasmant may publish in the future.

Co-authorship network of co-authors of D Vasmant

This figure shows the co-authorship network connecting the top 25 collaborators of D Vasmant. A scholar is included among the top collaborators of D Vasmant based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D Vasmant. D Vasmant is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vasmant, D. (2019). Maladie rénale chronique : prévention des risques de iatrogénies médicamenteuses et dépistage de la maladie. Néphrologie & Thérapeutique. 15(6). 465–467. 2 indexed citations
2.
3.
Joubert, Jean-Michel, Jacques‐Eric Gottenberg, Gilles Paintaud, et al.. (2014). Recherche translationnelle dans les pathologies immuno-inflammatoires : quels défis, quels progrès attendre, pour quelles innovations thérapeutiques ?. Therapies. 69(4). 291–296. 1 indexed citations
4.
Vasmant, D. (2009). Les pôles de compétitivité biomédicaux français : une opportunité pour la recherche partenariale public-privé en santé. Bulletin de l Académie Nationale de Médecine. 193(9). 2035–2044. 1 indexed citations
5.
Lièvre, Michel, Michel Marre, Gilles Châtellier, et al.. (2000). The Non–Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR) Study. Controlled Clinical Trials. 21(4). 383–396. 36 indexed citations
6.
Welsch, M, et al.. (1996). Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin‐angiotensin system. Fundamental and Clinical Pharmacology. 10(5). 474–483. 7 indexed citations
7.
Vray, Muriel, et al.. (1995). National Study of Obliterative Arterial Disease of the Lower Limbs Involving General Practitioners in France. Journal of Cardiovascular Pharmacology. 25. S51–S57. 4 indexed citations
8.
Soria, J, Manouchehr Mirshahi, Claudine Soria, et al.. (1995). Expression of Elastase and Fibrin in Venous Leg Ulcer Biopsies. Journal of Cardiovascular Pharmacology. 25. S101–S105. 20 indexed citations
9.
Bénétos, Athanase, et al.. (1991). Effects of Ramipril on Arterial Hemodynamics. Journal of Cardiovascular Pharmacology. 18. S153–S156. 1 indexed citations
10.
Bénétos, Athanase, et al.. (1991). Long lasting arterial effects of the ACE inhibitor ramipril.. PubMed. 5(5). 363–8. 9 indexed citations
11.
Bender, N., B Rangoonwala, J. Rosenthal, & D Vasmant. (1990). Physicochemical and enzyme binding kinetic properties of a new angiotensin-converting enzyme inhibitor ramipril and their clinical implications.. PubMed. 8 Suppl 1. 44–52. 9 indexed citations
12.
Becker, R. H. A., Udo Albus, Wolfgang Linz, et al.. (1989). High-Affinity Binding of the Converting Enzyme Inhibitor, Ramiprilat, to Isolated Human Glomeruli. Journal of Cardiovascular Pharmacology. 13. S31–S34. 1 indexed citations
13.
Bès, A., Pierre Corvol, V J Dzau, et al.. (1989). Circulating and Tissue Renin-Angiotensin System. Journal of Cardiovascular Pharmacology. 14(4). S60–S65. 1 indexed citations
14.
Albus, Udo, et al.. (1988). High affinity binding of ramiprilat on isolated human glomeruli. Biochemical Pharmacology. 37(24). 4679–4684. 1 indexed citations
15.
Vasmant, D, et al.. (1988). [Pharmacokinetics of prednisolone in children. Study of a correlation with tolerability and therapeutic effect in nephrosis].. PubMed. 17(13). 632–5. 4 indexed citations
16.
Bensman, A, J D Sraer, F Delarue, Marcelle Bens, & D Vasmant. (1987). Synthesis of Prostaglandins and Lipoxygenase Products by Rat Glomeruli during Development. Neonatology. 52(3). 149–156. 4 indexed citations
17.
Vasmant, D, et al.. (1986). [Acute renal insufficiency of glomerular origin and staphylococcal infection. Apropos of 2 pediatric cases].. PubMed. 33(3). 191–4. 1 indexed citations
18.
Vasmant, D, et al.. (1985). [Prenatal diagnosis of Fanconi's anemia].. PubMed. 14(30). 1612–1612. 1 indexed citations
19.
Vasmant, D, et al.. (1984). Pulse Methylprednisolone Therapy in Severe Idiopathic Childhood Nephrotic Syndrome. Acta Paediatrica. 73(6). 733–739. 28 indexed citations
20.
Bensman, A, et al.. (1984). Decreased biological activity of serum thymic hormone (thymulin) in children with nephrotic syndrome.. PubMed. 5(4). 201–4. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshie Segawa Breakdown of academic impact, for papers by P.E. de Jong Breakdown of academic impact, for papers by A. Chachati Breakdown of academic impact, for papers by Seema Basi Breakdown of academic impact, for papers by A. Ligabue Breakdown of academic impact, for papers by Luis Revert Breakdown of academic impact, for papers by Gerjan Navis Breakdown of academic impact, for papers by Pierre F. Faubert Breakdown of academic impact, for papers by J.-P. Chapelle Breakdown of academic impact, for papers by M. C. Laver
Rankless by CCL
2026